panitumumab,bevacizumab
takeda,amgen,roche
['paradigm']
 in her paradigm plenary discussion (who is owning #asco22 podiums by the way) observed a ~3.5 month *loss* of median os with bev first in 1st line l-sided ras/braf wt, mss colon cancer
Director, GI Oncology, @Intermountain. Interests: neuroendocrine tumors, cancer syndromes, empathy (even had a Whipple myself). Tweets my own.